Skip to main content

Regeneron Value Stock - Dividend - Research Selection

Regeneron Pharmaceuticals

ISIN: US75886F1075, WKN: 881535

Market price date: 17.05.2022
Market price: 667,56 USD


Regeneron Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 12-02-2022
Cash flow
Net operating cash flow 7.081.300.000
Capital Expenditures -3.395.000.000
Free cash flow 3.686.299.904
Balance sheet
Total Equity 18.769.000.000
Liabilities & Shareholders equity 25.434.000.000
Income statement
Net income 8.075.000.000
Eps (diluted) 71,970
Diluted shares outstanding 113.900.000
Net sales/revenue 16.071.700.000

Fundamental ratios calculated on: 17-05-2022

Ratios
Key figures 17-05-2022
Cash flow
P/C 10,54
   
P/FC 20,63
Balance sheet
ROI31,75
ROE73,80
Income statement
P/E9,28
Div. Yield0,00%
P/B3,98
P/S4,73


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolREGN
Market Capitalization74.605.641.728,00 USD
CountryUnited States
IndicesMSCI World Index,NASDAQ 100,NASDAQ Comp.,S&P 500
SectorsBiotechnology
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.regeneron.com


Description of the company

Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.regeneron.com


NEWS


Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur

2022-05-17
Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc. with participation from existing investors. Stine Seed Farms joins Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals Inc., Southeast Minnesota Capital Fund (SMCF), and several high-net-worth individuals on the Vyriad investment roster. This round adds to a prior closing for Vyriad's Ser

SEC filings reveal massive selling in media names, including Disney and Comcast

2022-05-16
Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

My 'Do Nothing Club' Returned 68% in the Past Year

2022-05-16
Stagnant stocks can sometimes be good buys

Regeneron Pharmaceuticals, Inc. - HIGH SCHOOL SCIENTISTS FROM AROUND THE WORLD WIN NEARLY $8M IN AWARDS, SCHOLARSHIPS AT REGENERON INTERNATIONAL SCIENCE AND ENGINEERING FAIR

2022-05-16
TARRYTOWN, N.Y. and WASHINGTON - Regeneron Pharmaceuticals, Inc. and Society for Science announced that Robert Sansone, 17, of Fort Pierce, FL, won the $75,000 top award in the 2022 Regeneron... | May 16, 2022

Top 5 1st Quarter Trades of Rhenman & Partners Asset Management AB

2022-05-16

Large Cap Biopharmaceuticals: Provide Growth, Value And Yield

2022-05-16

High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair

2022-05-13
Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Robert Sansone, 17, of Fort Pierce, FL, won the $75,000 top award in the 2022 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest global high school competition, for a project that explored high-efficiency alternatives to induction motors. Other top prizes went to projects in the fields of energy storage, biomedical engineering and robotics.

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

2022-05-13
AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical

2022-05-13
Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog

Top 5 1st Quarter Trades of Dodge & Cox

2022-05-13